Malaysia gives conditional approval for use of Ronapreve COVID-19 treatment

1 minute read
Register now for FREE unlimited access to Reuters.com

KUALA LUMPUR, Dec 14 (Reuters) - Malaysia's health ministry said on Tuesday it has given conditional approval for the use of the single-dose antibody cocktail Ronapreve, developed by Regeneron (REGN.O) and Roche (ROG.S), to treat COVID-19.

It has also approved a request from Merck & Co (MRK.N) for a clinical trial import license for its COVID-19 pill Molnupiravir, to be used as part of studies being conducted in Malaysia, the ministry said in a statement.

Register now for FREE unlimited access to Reuters.com
Reporting by Rozanna Latiff Editing by Ed Davies

Our Standards: The Thomson Reuters Trust Principles.